|16.07 1.01 (6.71%)||12-01 16:00|
|Targets||6-month :||19.79||1-year :||23.12|
|Resists||First :||16.95||Second :||19.79|
|Supports||First :||14.47||Second :||12.94|
|MAs||MA(5) :||14.78||MA(20) :||14.61|
|MA(100) :||17.93||MA(250) :||19.29|
|MACD||MACD :||-0.3||Signal :||-0.6|
|%K %D||K(14,3) :||69.1||D(3) :||49.5|
|52-week||High :||35.5||Low :||12.94|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ RCUS ] has closed Bollinger Bands are 36.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||16.1 - 16.16||16.16 - 16.21|
|Low:||14.28 - 14.34||14.34 - 14.4|
|Close:||15.94 - 16.05||16.05 - 16.14|
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||75 (M)|
|Shares Float||54 (M)|
|Held by Insiders||29.9 (%)|
|Held by Institutions||77.6 (%)|
|Shares Short||6,920 (K)|
|Shares Short P.Month||6,620 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||6.94|
|Profit Margin||-244.2 %|
|Operating Margin||-250 %|
|Return on Assets (ttm)||-15.7 %|
|Return on Equity (ttm)||-48.1 %|
|Qtrly Rev. Growth||-3 %|
|Gross Profit (p.s.)||-2.36|
|Sales Per Share||1.6|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||-288 (M)|
|Levered Free Cash Flow||-161 (M)|
|Price to Book value||2.31|
|Price to Sales||10.01|
|Price to Cash Flow||-4.18|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|